Anticoagulation therapy in children with SARS-CoV-2 pneumonia: a retrospective observational study on dosage, efficacy, and safety.
4 affiliations
- 1University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
- 2Children's Hospital 1, Ho Chi Minh City, Vietnam.
- 3University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. [email protected].
- 4Children's Hospital 1, Ho Chi Minh City, Vietnam. [email protected].
Abstract
Background
Coagulopathy is a significant complication in pediatric COVID-19, yet optimal anticoagulation dosing in children remains uncertain due to the lack of randomized controlled trials. This study aimed to compare the efficacy and safety of prophylactic versus therapeutic anticoagulation dosing in children hospitalized with SARS-CoV-2 pneumonia.Methods
A retrospective observational study was conducted at Children's Hospital 1 in Ho Chi Minh City, Vietnam, from July 2021 to May 2022. Pediatric patients with confirmed COVID-19 who received enoxaparin were included. Following the national paediatric protocol, patients were stratified by enoxaparin dose into a prophylactic-dose group (0.5 mg/kg every 12 h; total ≤ 1 mg/kg/day) and a therapeutic-dose group (1 mg/kg every 12 h; total > 1 mg/kg/day). Because thrombotic events and deaths were rare, length of hospital stay and changes in inflammatory and coagulation biomarkers were examined as exploratory surrogate outcomes, while in-hospital mortality and bleeding events were reported descriptively. Multivariable regression and inverse probability of treatment weighting (IPTW) were used to reduce, but not eliminate, confounding by indication.Results
Of 181 eligible patients, 140 were included (99 prophylactic-dose, 41 therapeutic-dose). The therapeutic-dose group had a higher proportion of severe/critical disease (82.9% vs. 55.6%, p = 0.003). After multivariable adjustment, therapeutic dosing was not associated with a significant difference in length of hospital stay (β = 0.041, 95% CI: -0.165 to 0.246, p = 0.698), changes in D-dimer (β = 0.195, p = 0.797), C-reactive protein (β = 0.122, p = 0.985), or ferritin levels (β = 191.6, p = 0.509). No thrombotic events occurred in either group. In-hospital mortality was low (5/140, 3.6%) and did not differ between the prophylactic- and therapeutic-dose groups (4.0% vs. 2.4%, p = 1.000). Major bleeding was confined to two patients (4.9%) in the therapeutic-dose group; with only two events, no reliable safety comparison between dosing strategies was possible. IPTW sensitivity analysis was consistent with these results.Conclusions
After adjusting for disease severity and other confounders, we did not detect a statistically significant difference in efficacy outcomes between prophylactic- and therapeutic-dose anticoagulation. Because of the retrospective design, small sample, strong confounding by indication, and the absence of thrombotic events, these findings are exploratory and hypothesis-generating; the lack of a statistically significant difference should not be interpreted as evidence of equivalence between the two strategies. Prospective, adequately powered studies are needed before any dosing strategy can be recommended for children with SARS-CoV-2 pneumonia, particularly in resource-limited settings where anti-Xa monitoring is unavailable.
Related
- Development and internal validation of a nomogram for predicting flexible bronchoscopy utilization in children with lobar pneumonia caused by Mycoplasma pneumoniae: a single-center retrospective cohort study
- Optimizing Polymyxin B Exposure in Carbapenem-Resistant Organism-Associated Hospital-Acquired Pneumonia: A Retrospective Observational Study.
- Pathogen spectrum and triple-criteria interpretation algorithm of BALF-targeted NGS in children with refractory severe community-acquired pneumonia in mountainous Northeastern Sichuan: a single-center retrospective study.
- Factors associated with severe disease and in-hospital mortality in children with non-HIV-associated Pneumocystis jirovecii pneumonia: a single-center retrospective cohort study
- The Safety and Efficacy of a Transbronchial Lung Cryobiopsy Using a 1.7-mm Cryoprobe in Older Adult Patients with Suspected Interstitial Lung Disease: A Single-center, Retrospective, Observational Study
BibTeX
@article{phung2026anticoagulation,
title = {{Anticoagulation therapy in children with SARS-CoV-2 pneumonia: a retrospective observational study on dosage, efficacy, and safety.}},
author = {Nguyen The Nguyen Phung and Thuc Thanh Tran and Nghia Van Nguyen and Dung Hoang Nguyen and Mai Anh Thi Nguyen},
journal = {BMC pediatrics},
year = {2026},
month = jul,
doi = {10.1186/s12887-026-07392-3},
url = {https://europepmc.org/article/MED/42902242},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Anticoagulation therapy in children with SARS-CoV-2 pneumonia: a retrospective observational study on dosage, efficacy, and safety.
AU - Nguyen The Nguyen Phung
AU - Thuc Thanh Tran
AU - Nghia Van Nguyen
AU - Dung Hoang Nguyen
AU - Mai Anh Thi Nguyen
PY - 2026
DA - 2026/07/01
JO - BMC pediatrics
DO - 10.1186/s12887-026-07392-3
UR - https://europepmc.org/article/MED/42902242
AB - Background Coagulopathy is a significant complication in pediatric COVID-19, yet optimal anticoagulation dosing in children remains uncertain due to the lack of randomized controlled trials. This study aimed to compare the efficacy and safety of prophylactic versus therapeutic anticoagulation dosing in children hospitalized with SARS-CoV-2 pneumonia.Methods A retrospective observational study was conducted at Children's Hospital 1 in Ho Chi Minh City, Vietnam, from July 2021 to May 2022. Pediatric patients with confirmed COVID-19 who received enoxaparin were included. Following the national paediatric protocol, patients were stratified by enoxaparin dose into a prophylactic-dose group (0.5 mg/kg every 12 h; total ≤ 1 mg/kg/day) and a therapeutic-dose group (1 mg/kg every 12 h; total > 1 mg/kg/day). Because thrombotic events and deaths were rare, length of hospital stay and changes in inflammatory and coagulation biomarkers were examined as exploratory surrogate outcomes, while in-hospital mortality and bleeding events were reported descriptively. Multivariable regression and inverse probability of treatment weighting (IPTW) were used to reduce, but not eliminate, confounding by indication.Results Of 181 eligible patients, 140 were included (99 prophylactic-dose, 41 therapeutic-dose). The therapeutic-dose group had a higher proportion of severe/critical disease (82.9% vs. 55.6%, p = 0.003). After multivariable adjustment, therapeutic dosing was not associated with a significant difference in length of hospital stay (β = 0.041, 95% CI: -0.165 to 0.246, p = 0.698), changes in D-dimer (β = 0.195, p = 0.797), C-reactive protein (β = 0.122, p = 0.985), or ferritin levels (β = 191.6, p = 0.509). No thrombotic events occurred in either group. In-hospital mortality was low (5/140, 3.6%) and did not differ between the prophylactic- and therapeutic-dose groups (4.0% vs. 2.4%, p = 1.000). Major bleeding was confined to two patients (4.9%) in the therapeutic-dose group; with only two events, no reliable safety comparison between dosing strategies was possible. IPTW sensitivity analysis was consistent with these results.Conclusions After adjusting for disease severity and other confounders, we did not detect a statistically significant difference in efficacy outcomes between prophylactic- and therapeutic-dose anticoagulation. Because of the retrospective design, small sample, strong confounding by indication, and the absence of thrombotic events, these findings are exploratory and hypothesis-generating; the lack of a statistically significant difference should not be interpreted as evidence of equivalence between the two strategies. Prospective, adequately powered studies are needed before any dosing strategy can be recommended for children with SARS-CoV-2 pneumonia, particularly in resource-limited settings where anti-Xa monitoring is unavailable.
SN - 1471-2431
ER -